Surgical Therapy an Chemoradiotherapy for Postoperative Recurrent Esophageal Cancer

被引:4
作者
Kubota, Keisuke [1 ]
Kuroda, Junko [1 ]
Yoshida, Masashi [1 ]
Ohta, Keiichiro [1 ]
Suwa, Tatsushi [1 ]
Mafune, Ken-ichi [1 ]
Kawase, Takatsugu [2 ]
Kitahara, Tadashi [2 ]
Kubo, Atsushi [2 ]
Kitajima, Masaki [1 ]
机构
[1] Int Univ Hlth & Welf, Mita Hosp, Dept Surg Gastroenterol, Tokyo 1088329, Japan
[2] Int Univ Hlth & Welf, Mita Hosp, Tokyo 1088329, Japan
关键词
Recurrent esophageal cancer; Surgical resection; Chemoradiotherapy; RADIATION-THERAPY; CONCURRENT CHEMORADIOTHERAPY; CISPLATIN; 5-FLUOROURACIL;
D O I
10.5754/hge.11200
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: A retrospective analysis Of therapeutic modalities used in postoperative recurrent esophageal canter. Methodology: Among 43 esophageal cancer patients who underwent esophagectomy between 2003 and 2010, recurrence was found in 15: Best supportive care was given-to two patients and another patient was referred to another hospital. The remaining 12 patients were treated by the following modalities: Surgical resection: 2 cases; chemoradiotherapy: 7 cases; chemotherapy: 2 cases; and radiotherapy: 1 case. The median survival time, 1-year survival rates, and response rates :were examined. Data from 13 esophageal canter patients who underwent chemoradiotheray as an initial therapy in the same period were collected and compared-with recurrent cases treated with chemoradiotherapy. Results: For all 12 patients, the median overall survival time was 19.5 months, and the 1-year survival rate was 83%. Among 7 chemoradiotherapy patients, the response rate was 57%. The median survival time was 23 months, and,the 1-year survival rate was 86%. The response rate of 13 patients receiving chemoradiotherapy as an initial therapy was 69%. The median overall survival time was 12 months and the 1-year survival rate was 54%. Conclusions: Re-operation and chemoradiotherapy for recurrent esophageal cancer might be as effective as the same treatment used initially.
引用
收藏
页码:1961 / 1965
页数:5
相关论文
共 13 条
[1]   A systematic overview of radiation therapy effects in oesophageal cancer [J].
Ask, A ;
Albertsson, M ;
Järhult, J ;
Cavallin-Ståhl, E .
ACTA ONCOLOGICA, 2003, 42 (5-6) :462-475
[2]   Bi-weekly chemotherapy of paclitaxel and cisplatin in patients with metastatic or recurrent esophageal cancer [J].
Cho, SH ;
Chung, LJ ;
Song, SY ;
Yang, DH ;
Byun, JR ;
Kim, YK ;
Lee, JJ ;
Na, KJ ;
Kim, HJ .
JOURNAL OF KOREAN MEDICAL SCIENCE, 2005, 20 (04) :618-623
[3]   Results of radiation therapy combined with nedaplatin (cis-diammine-glycoplatinum) and 5-Fluorouracil for postoperative locoregional recurrent esophageal cancer [J].
Jingu, K ;
Nemoto, K ;
Matsushita, H ;
Takahashi, C ;
Ogawa, Y ;
Sugawara, T ;
Nakata, E ;
Takai, Y ;
Yamada, S .
BMC CANCER, 2006, 6 (1)
[4]  
Kato H, 2005, ANTICANCER RES, V25, P3461
[5]  
Komatsu S, 2005, HEPATO-GASTROENTEROL, V52, P796
[6]  
Kubota K, 2001, HEPATO-GASTROENTEROL, V48, P1364
[7]   Complete regression of advanced esophageal cancer with abdominal bulky lymph node metastasis treated by concurrent chemoradiotherapy using docetaxel, cisplatin, and 5-fluorouracil [J].
Kubota, Keisuke ;
Mafune, Ken-ichi ;
Yamada, Kazuhiko ;
Yamashita, Hideomi ;
Kuroda, Junko ;
Aikou, Susumu ;
Kaminishi, Michio .
ESOPHAGUS, 2009, 6 (03) :183-187
[8]   Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease [J].
Mariette, C ;
Balon, JM ;
Piessen, G ;
Fabre, S ;
Van Seuningen, I ;
Triboulet, JP .
CANCER, 2003, 97 (07) :1616-1623
[9]   Radiation therapy for loco-regionally recurrent esophageal cancer after surgery [J].
Nemoto, K ;
Ariga, H ;
Kakuto, Y ;
Matsushita, H ;
Takeda, K ;
Takahashi, C ;
Takai, Y ;
Yamada, S ;
Hosoi, Y .
RADIOTHERAPY AND ONCOLOGY, 2001, 61 (02) :165-168
[10]   Concurrent chemoradiotherapy with protracted infusion of 5-FU and cisplatin for postoperative recurrent or residual esophageal cancer [J].
Nishimura, Y ;
Koike, R ;
Nakamatsu, K ;
Kanamori, S ;
Suzuki, M ;
Shigeoka, H ;
Shiozaki, H .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2003, 33 (07) :341-345